Infection of Omicron BA.5.2 in patients provides broad immune responses against SARS-CoV-2-Reference-Cited by-同舟云学术

Infection of Omicron BA.5.2 in patients provides broad immune responses against SARS-CoV-2

Published:2023-11-28 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Li Le¹,Feng Tang²,Shen Quan³,Wang Ning⁴,Shi Xiaoshan³,Wei Zhigong²,Chen Wanze³,Yang Fan⁵,Zhu Yueting²,Zhang Chengxin¹,Zhang Shuang²,Xie Xin⁶,Bai Haiqing⁶,Fu Shengwei¹,Liu Jiyan²,Si Longlong⁷

Affiliation:

1. Key Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.

2. Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.

3. Key Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China. University of Chinese Academy of Sciences, Beijing 100049, China.

4. Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.

5. University of Chinese Academy of Sciences, Beijing 100049, China. Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.

6. Xellar Biosystems, Newton, MA, 02458, USA.

7. Key Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China. Chinese Academy of Sciences

Abstract

Abstract The host immunity induced by wide spread of Omicron variants and its influence on emerging SARS-CoV-2 variants are attracting broad attention. Here we report that the natural infection with Omicron BA.5.2 induce broad cross-reactive immunity against SARS-CoV-2 variants, which could reduce the risk of next wave of SARS-CoV-2 infection.

Publisher

Research Square Platform LLC

Reference13 articles.

1. Repeated vaccination of inactivated SARS-CoV-2 vaccine dampens neutralizing antibodies against Omicron variants in breakthrough infection;Gao B;Cell Res,2023

2. Modeling transmission of SARS-CoV-2 Omicron in China;Cai J;Nat Med,2022

3. nature medicine-An equitable route forward from China’s ‘zero COVID’ policy;Wang ZC;Nat Med,2023

4. National Health Commission. http://www.nhc.gov.cn/xcs/kpzs/202302/b4ea6edab acf4061a0bde4fff649d35e.shtml. 2023.

5. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China:A descriptive study;Chen N;Lancet,2020